SK bioscience appoints new executives
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Subscribe To Our Newsletter & Stay Updated